Valvular heart disease, particularly aortic stenosis and mitral regurgitation, accounts for a large proportion of cardiology practice, and their prevalence is predicted to increase. Management of the asymptomatic patient remains controversial. Biomarkers have been shown to have utility in the management of cardiovascular disease such as heart failure and acute coronary syndromes. In this state-of-the-art review, we examine the current evidence relating to natriuretic peptides as potential biomarkers in aortic stenosis and mitral regurgitation. The natriuretic peptides correlate with measures of disease severity and symptomatic status and also can be used to predict outcome. This review shows that natriuretic peptides have much promise as biomarkers in common valvular heart disease, but the impact of their measurement on clinical practice and outcomes needs to be further assessed in prospective studies before routine clinical use becomes a reality. (J Am Coll Cardiol 2010;55: 2034-48)
Surveillance of valvular heart disease accounts for a significant proportion of outpatient attendances in cardiology. The predicted prevalence may double within 20 years due to an aging population (1) . Patient management usually involves monitoring for clinical symptoms or functional deterioration usually assessed by imaging studies, of which transthoracic echocardiography is the mainstay. A biomarker is defined as a biological molecule that can be identified in a particular disease and additionally may be able to assess the severity and prognosis or monitor the response to treatment of that disease state. This is an attractive prospect in valvular heart disease. A robust biomarker could potentially eliminate the need for some costly imaging studies during routine surveillance and aid in management decisions, particularly with regard to the optimum timing for surgical or percutaneous intervention. Natriuretic peptides are endogenous cardiac hormones and have shown utility as biomarkers in heart failure, both for diagnosis (2) and to monitor and guide therapy (3, 4) , and, in ischemic heart disease, as a predictor of outcome (5) (6) (7) . This review examines natriuretic peptides as potential biomarkers in the most commonly managed valvular heart diseases, aortic stenosis (AS) and mitral regurgitation (MR).
Natriuretic Peptides
Three types of natriuretic peptides have been identified: B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and C-type natriuretic peptide (CNP). Their physiology has been reviewed in detail elsewhere (8 -11) . Briefly, CNP is structurally distinct from ANP and BNP. CNP is expressed to a much greater extent in the central nervous system and vascular tissues than in the heart (12), acting as a potent vasorelaxant and inhibitor of vascular smooth muscle proliferation and endothelial cell migration (11) . BNP and ANP exist as pro-hormones that are cleaved into inactive N-terminal fragments (N-terminal proBNP [NTproBNP] , N-terminal proANP [NT-proANP] ) and biologically active hormones (BNP, ANP) before release into the circulation. The N-terminal fragments are more stable in vivo and are often used as surrogate markers for the biologically active hormone (8) . The predominant cardiac source of ANP is the atria and the ventricles are the main cardiac source of BNP, although both can be synthesized in either chamber. ANP is stored in granules, whereas BNP is released in bursts regulated by gene transcription (13) (14) (15) The stimulus for ANP and BNP release is primarily myocyte stretch, but endothelin-I, nitric oxide, and angiotensin II may all have a role. ANP concentrations are more closely related to left atrial (LA) pressure and BNP to left ventricular (LV) pressure (16, 17) . Three natriuretic peptide receptors (NPRs) have been identified; NPR-A and NPR-B, which mediate their biological action, and NPR-C, which is a clearance receptor (18) . Natriuretic peptides cause natriuresis, diuresis, and vasorelaxation, reducing blood pressure and preload (11) . BNP has direct lusitropic (relaxing) properties in the myocardium (19) . ANP and BNP have been shown in vitro to have the effect of inhibiting the synthesis of collagen by cardiac fibroblasts (20, 21) . Additionally, natriuretic peptides, their processing enzymes, and their receptors are expressed in the cardiac valves themselves (22) . The close links between natriuretic peptides and cardiovascular structure, function, and hemodynamics are clear; however, current understanding of the molecular biology is far from complete (8) .
Methods
A systematic search of peer-reviewed literature until September 2009 using PubMed was performed. The search terms "biomarkers," "natriuretic peptide," "BNP," "NTproBNP," "ANP," and "CNP" were combined and then coupled with each of "aortic stenosis" and "mitral regurgitation." Predefined limits were: 1) the main body of text of the article needed to be in English; 2) human adult subjects; 3) prospective, retrospective, and randomized studies were included; 4) reviews and case reports or studies with Ͻ10 patients were excluded; and 5) only studies in which a group containing at least mild isolated AS or isolated MR, which had been well characterized and specifically analyzed (primarily or as a substudy), were included. Studies including patients with mixed valve disease or severe valvular lesions in addition to the valve lesion of interest were excluded. Studies were included irrespective of the presence of other comorbidities including coronary artery disease (CAD) and symptoms.
Results
In AS, 41 studies of natriuretic peptides were appropriate for review. Details of the important studies are presented in Tables 1 through 3 for baseline correlations, unoperated, and post-operative outcome, respectively. In MR, 9 studies of natriuretic peptides were appropriate for review. Details of baseline correlations are given in Table 4 , and predictors of outcome are shown in Table 5 .
For both valvular diseases, the studies reviewed have significant clinical and methodological diversity, particularly with regard to measures of outcome. This heterogeneity does not lend itself to a meaningful meta-analysis, and therefore we present a systematic review using a more qualitative approach to combining results. Where the distribution of natriuretic peptide measurements is significantly skewed, they have been logarithmically transformed in the original studies before analysis.
Natriuretic Peptides in AS
Clinical decision making in AS. AS is the most common valve lesion requiring surgery in the developed world (23) . The survival of patients with symptomatic AS is dismal, and the prognosis is greatly improved by aortic valve replacement (AVR), which is universally recommended (24) . In contrast, management of patients with moderate to severe asymptomatic AS is a controversial area and has been the subject of hot debate among cardiologists and cardiac surgeons for Ͼ40 years (25, 26) . Traditionally, the risk of sudden cardiac death in asymptomatic patients has been regarded as low, typically Ͻ1% (27, 28) . However, rates of almost 5% per year have been reported where a rigid policy of not operating on asymptomatic patients was adhered to (29) . Additionally, with a watchful waiting approach to guide surgery, concerns include patients not promptly seeking help when they become symptomatic and the risk of mortality while awaiting surgery when symptomatic (30) . Over the past decade, several important prospective studies have been published on the natural history of asymptomatic AS incorporating echocardiographic measures of severity, functional testing, the subsequent development of symptoms, need for AVR, and death (27) (28) (29) (31) (32) (33) (34) . Even in research study populations, significant numbers underwent AVR while asymptomatic at the discretion of the referring physician. These patients tended to be older and have more severe disease (27, 28) . This variation in clinical practice, along with differences between the American College of Cardiology/American Heart Association and the European Society of Cardiology guidelines (35, 36) , reflect the uncertainty regarding the best way to manage these patients (37) . Potential role of natriuretic peptides in valve disease. It is clear from the currently available evidence that, in the absence of a randomized, controlled trial of surgery, better risk stratification of asymptomatic patients with moderate to severe AS and MR is still required, and biomarkers have a role to play. A useful biomarker would reflect disease severity, increase with progression of disease, reflect subclinical myocardial dysfunction, discriminate between patients in whom symptoms do and do not develop in the short to medium term, and be easily and reliably measured. The ideal biomarker would also allow the identification of a high-risk individual with severe disease before the development of symptoms who could undergo valve surgery without increased perioperative mortality. The presence of AS almost universally has been associated with increased levels of natriuretic peptides when compared with controls (17, 38, 39) , even in asymptomatic mild AS (40, 41) . This is supported by increased BNP messenger RNA in myocardial samples (42) . The N-terminal forms correlate closely with the parent molecules as expected (17) . BNP and ANP levels could also distinguish between AS and CAD patients undergoing cardiac surgery, with BNP being the better discriminator (41) . BNP (43, 44) and NT-proBNP (45) at baseline weakly but significantly correlated with age.
SEVERITY OF VALVE DISEASE. Natriuretic peptide levels correlate modestly with measures of AS severity on TTE.
There is a modest inverse correlation with aortic valve area (AVA) and a slightly weaker positive correlation with peak and mean pressure gradient in the majority of studies ( Table 1 , Fig. 1 ).
CARDIAC STRUCTURE AND FUNCTION.
There is a significant association between LV mass index (LVMI) and BNP (17,38,43,44,46 -48) and NT-proBNP (17, 40, 45, 48, 49) .
Results for ANP are variable, with some studies showing a correlation (17, 48) and others not (39, 41) . NT-proBNP is significantly increased relative to controls already in the lowest LVMI quartile (78 to 139 g/m 2 ); in comparison, NT-proANP was increased over controls only from the second quartile (141 to 180 g/m 2 ) and above (17) . The receiver-operator curve analyses in this study showed that BNP and NT-proBNP were most accurate in the detection of increased LVMI, whereas NT-proANP performed best in the detection of increased LA pressure, measured invasively (17) . Thus, an elevation of BNP/NTproBNP levels in the circulation, with little or no increase in ANP/NT-proANP, may indicate a relatively early stage of AS, when LV hypertrophy compensates for the increase in afterload without preload increase, whereas the combined elevation of both natriuretic peptides may indicate a more advanced stage. Right ventricular systolic pressure also correlates with BNP, NT-proBNP, and ANP (48) . Of note, eccentric LV hypertrophy was associated with a significantly higher serum BNP level than concentric-type hypertrophy (44) . Elsewhere, eccentric hypertrophy has been associated with the most impaired systolic function and the worst clinical picture, and it is postulated that this represents the end stage of pressure overload (50) .
Natriuretic peptides correlate with markers of systolic function; BNP, ANP, and their N-terminal fragments correlate inversely with LVEF (43, 45, 46, 48, 51, 52) , and fractional shortening (17, 41) . NT-proBNP also correlates with tissue Doppler imaging systolic velocity (53) . Natriuretic peptides also correlate with echocardiographic measures of diastolic function (46, 48) , although in the Gerber et al. (48) study, the majority additionally had systolic dysfunction. The early diastolic transmitral velocity (E) corrected for the influence of relaxation, the early diastolic velocity of the mitral annulus (Em), the E/Em ratio, is a marker of diastolic dysfunction (54) . This correlates significantly with NT-proBNP in severe symptomatic AS (53) and better with NT-proBNP than AVA in mild to moderate AS (55) and also is the strongest correlate in asymptomatic patients (r ϭ 0.53, p ϭ 0.001) (40) . Wall stress is an important stimulus to natriuretic peptide production. LV end-systolic midwall wall stress, calculated by the method of Grossman et al. (56) , highly correlated with BNP (r ϭ 0.96, p Ͻ 0.0001) (41), ANP (41, 48) , and NT-proBNP (48), as did LV end-diastolic wall stress (47) . NT-proBNP is significantly related to mean LV strain (r ϭ 0.61, p Ͻ 0.001) (49 (58) . NT-proBNP remained higher in symptomatic patients after adjustment for age, sex, creatinine level, AVA, and LVEF, a mean 1.74 times higher (95% CI: 1.12 to 2.69, p ϭ 0.014). This held true even when the AVA was Ͻ1 cm 2 (48) , although another study suggests that only BNP, and not NTproBNP, was useful for those with severe AS (60) .
In symptomatic patients, natriuretic peptides increase with New York Heart Association (NYHA) functional class, irrespective of the severity of the AS (38, 45, 46, 48, 61) . Differentiating asymptomatic from minimally symptomatic (i.e., NYHA functional classes I and II) is more difficult, with one study showing a significant difference (58) and another not (51) . BNP can identify with good diagnostic accuracy patients in NYHA functional class III to IV; the area under the receiver-operator curve was 0.78 (95% CI: 0.66 to 0.87; best cutoff was 254.64 pg/ml) (46) . In contrast to NYHA functional class, angina and syncope do not seem to be related to natriuretic peptides (46, 48, 58) , highlighting the possible different pathophysiologies of these symptoms compared with dyspnea.
RESPONSE TO EXERCISE.
In asymptomatic or minimally symptomatic AS, higher plasma levels of BNP are a better predictor of an abnormal blood pressure response to exercise than echocardiographic measures of severity (62) . In moderate to severe asymptomatic AS, BNP was associated with lower peak velocity of the mitral valve annulus on exercise and reduced exercise capacity compared with controls (63) . Both of these studies only included patients with LVEF Ͼ50%. Taken together, these reports suggest that elevated BNP reflects a reduced myocardial functional reserve and is therefore indicative of LV dysfunction with exercise despite normal measures of systolic function at rest in asymptomatic AS. NT-proBNP had no predictive value for those undergoing AVR CABG ϭ coronary artery bypass graft; LRHC ϭ left-right heart catheterization; LVEF ϭ left ventricular ejection fraction; NYHA ϭ New York Heart Association; other abbreviations as in Tables 1 and 2 .
Continued
CAD. The prevalence of CAD in AS is significant and has been reported as Ͼ50% (64) . Unless coronary angiography has been performed in all patients included in a study, the exact prevalence is unclear; estimations are usually made on the basis of clinical history. This is reflective of the clinical setting during the surveillance of asymptomatic patients with AS when the presence or absence of coexisting CAD is unknown. In AS patients with associated CAD, there are reports of increased BNP (52) and NT-proBNP (65) or no effect on NT-proBNP (61 Steadman et al. May 11, 2010 May 11, :2034 Natriuretic Peptides in Valvular Heart Disease commented on the impact of CAD on outcome. As this is not always well described, it is a potential confounding factor and a recognized limitation when using biomarkers to assess AS. Prediction of outcome in unoperated patients. SYMPTOM ONSET. Asymptomatic patients in whom symptoms develop during follow-up have higher levels of BNP (51), NT-proBNP (51, 66) , and NT-proANP (51) at baseline. Patients with at least mild AS and a plasma level of NT-proBNP that exceeded normal limits (Ͼ50 pmol/l) at baseline were more likely to have symptoms develop (55%) than patients with levels of NT-proBNP within normal limits (11%) (OR: 9.6, 95% CI: 2 to 64, p ϭ 0.02) (66) . AVA, peak aortic velocity, and LVEF were less reliable predictors of symptomatic onset (66) . In severe AS, symptom-free survival at 3, 6, 9, and 12 months was best separated by NT-proBNP levels of Ͻ80 pmol/l versus Ͼ80 pmol/l: 100% versus 92%, 88% versus 58%, 88% versus 35%, and 69% versus 18%, respectively (51) . Those in whom symptoms developed did not differ significantly with regard
Outcome in MR to age, peak and mean gradients, and the presence of CAD. They had a slightly smaller AVA and slightly lower LVEF; however, by multivariate analysis, only NT-proBNP (p Ͻ 0.05) and LVEF (p Ͻ 0.05) were independent predictors of remaining free of symptoms during follow-up (51).
Survival/major adverse cardiovascular events (MACE).
In an elderly cohort of 124 unoperated patients with moderate to severe AS, survival was significantly influenced by the presence of symptoms (relative risk: 7.5, p Ͻ 0.01) and BNP tertile (relative risk: 2.9, p Ͻ 0.001) (57) . The 1-year mortality rate without surgery was 6%, 34%, and 60% with each increasing tertile. No patients with BNP Ͻ100 pg/ml died (57) . The combination of BNP and symptoms provided a better prediction of survival than symptoms alone (chi-square 13.6, p Ͻ 0.001) (57) . BNP significantly (relative risk: 2.8, p Ͻ 0.01) influenced survival after correction for other univariate predictors: CAD, symptoms, NYHA functional class, LVEF, and AVA (57) . Two other studies in patients with variable severity of AS, many of whom had symptoms or in whom symptoms developed but were still predominantly managed medically, have also shown increased mortality or hospitalization with heart failure in those with elevated BNP (46) or NT-proBNP (45) . In the Weber et al. (45) study of the conservatively managed patients with an adverse outcome, only one-third (n ϭ 3) had severe AS, and, compared with event-free survivors, the prevalence of CAD was almost double and LVEF was significantly lower. In the Antoni-Canterin et al. (46) study, despite 24 patients being of NYHA functional classes III to IV, only 2 had AVR (46) . These studies are unlikely to be representative of those patients being followed serially and being considered for surgery with the development of symptoms.
PREDICTING MACE INCLUDING AVR. Three relatively small studies in patients with asymptomatic mild-severe AS have shown that those with elevated levels of NT-proBNP are more likely to die, be hospitalized, or need AVR due to the development of symptoms (55, 67, 68 ] ϩ (natural logarithm of BNP ϫ 1.5) ϩ 1.5 (if female sex), which was subsequently validated in another 107 patients from Belgium. MACE were largely driven by positive exercise tests leading to referral for AVR while still asymptomatic. Although these studies clearly demonstrate the potential of BNP/NT-proBNP as useful prognostic markers in asymptomatic AS, they do not give us evidence that operating on asymptomatic patients with high levels leads to a reduction in mortality or better functional outcome.
Predictors of post-operative outcome. CARDIAC FUNCTION.
In the hours after surgical AVR for AS, there is an increase in BNP (70) and ANP (71) . BNP then decreases significantly at 6 and 12 months post-AVR but does not return to normal (44, 61) . Decreases occur in parallel with decreases in mean transvalvular pressure gradient and left ventricular mass (72) , with patients with the largest post-operative valve area index having the largest decrease in NT-proBNP (73) . The fact that BNP levels were still elevated postoperatively might indicate that BNP is a marker of insufficient reverse remodeling with ongoing stimulus for BNP synthesis. Alternatively, because BNP inhibits myocyte growth and fibrosis (74) , it may have a more direct role in the reverse-remodeling process. Mean myocardial systolic strain increases after AVR, which occurs in parallel with decreases in LVMI, both of which are independently related to changes in NT-proBNP (r ϭ Ϫ0.67, p Ͻ 0.001; r ϭ Ϫ0.71, p Ͻ 0.001) during 12 months of follow-up after AVR (49) . NT-proBNP is a significant predictor of normal post-operative LVEF, along with pre-operative LVEF, by multivariate analysis (51) . Post-operative changes in LA volume and LA pressure were reflected in ANP (49) and NT-proANP (73) levels, respectively. Persistently high NT-proANP seems to be predictive of late post-operative atrial fibrillation (AF), consistent with high LA pressure being an important determinant of AF (75) .
SYMPTOMS.
Three studies demonstrated that high preoperative BNP/NT-proBNP levels are associated with decreased symptomatic improvement in AS patients (47, 51, 72) . Patients in whom there is no symptomatic improvement tend to have nonsignificant decreases in NT-proBNP and LVMI even though the transvalvular pressure gradient decreases (72) . Seventeen of 40 patients with symptomatic AS who underwent AVR and in whom symptoms of left-sided heart failure, right-sided heart failure, or hypotension developed in-hospital were characterized by significantly higher baseline pre-operative BNP levels (399 Ϯ 82 pg/ml vs. 124 Ϯ 41 pg/ml, p ϭ 0.011), end-diastolic wall stress, and pulmonary capilliary wedge pressure but with similar severity of AS and systolic function (47) .
SURVIVAL.
Three moderately large studies examined the prognostic value of BNP/NT-proBNP for survival in operated patients with severe AS (51, 52, 72) and a fourth reported on 70 patients, of whom 43 had AVR (58) . Two studies showed that NT-proBNP (51) and BNP (52) were independent predictors of perioperative mortality. The latter study also demonstrated the superiority of BNP in the prediction of perioperative and long-term mortality compared with the commonly used logistic EuroSCORE (52). These results tend to be supported by Lim et al. (58)
Natriuretic Peptides in Valvular Heart Disease although the mortality results included death in 7 patients who did not have surgery. The 4 patients who did have AVR and died all had increased BNP (58) . In contrast, however, NT-proBNP was not predictive of survival or hospitalization for heart failure in 102 patients with severe AS undergoing AVR (45) . There is not a clear explanation why these results differed but may be related to the lower frequency of concomitant coronary artery bypass graft and slightly younger age of patients in the Weber et al. (45) study compared with the Pedrazzini et al. (52) study (29% vs. 42% coronary artery bypass graft, 69 Ϯ 10 years vs. 73 Ϯ 9 years, respectively). Low-flow, low-gradient aortic stenosis. BNP is higher in patients with truly severe compared with pseudosevere AS and correlates with AS severity and LVEF (76) . BNP was a strong predictor of outcome. With BNP levels Ն550 pg/ml, the cumulative 1-year survival rate of the total cohort when compared with those with BNP levels Ͻ550 pg/ml was 47 Ϯ 9% versus 97 Ϯ 3% (p Ͻ 0.0001), and the postoperative survival rate was 53 Ϯ 13% versus 92 Ϯ 7% (76) . When subdivided into truly severe and pseudosevere AS, the groups were too small for statistical analysis; however, a consistent pattern of higher mortality was observed in patients with BNP Ն550 pg/ml. The poorer survival in patients with high BNP/NT-proBNP undergoing AVR does suggest that those patients may have more irreversible myocardial dysfunction, which may be directly related to overt replacement myocardial fibrosis (77) .
Natriuretic Peptides in MR
Clinical decision making in MR. MR is the second most common form of valve disease. MR may be divided into organic and functional, depending on whether the valve leaflets or chords themselves are abnormal or whether the leak reflects an abnormality of the supporting structures. In the developed world, degenerative valve disease is the most common cause of moderate or severe MR, with endocarditis and rheumatic disease making up most of the remainder. Ischemic heart disease is the most common cause of functional MR. Chronic MR, if sufficiently severe, leads to volume overload of the left ventricle, which in turn results in compensatory chamber dilation and eccentric hypertrophy. The transition to a decompensated state is poorly understood but might be due to a progressive increase in regurgitant volume, a decrease in contractility, an increase in afterload, or a combination of these factors (78) . It is usually associated with the onset of symptoms but may be insidious. The decompensated state is characterized by marked ventricular dilation, increased diastolic pressure, increased systolic wall stress, and a decrease in ejection fraction to less than 60%. In most instances, the management of functional MR is treating the underlying condition, whereas in organic MR, therapy is targeted at the specific valvular abnormality. Current guidelines for the management of severe organic MR reflect strong evidence that surgical intervention is best performed before the onset of limiting symptoms or even a minor reduction in LVEF (35, 79, 80) . Wherever possible, mitral valve repair is a better option than valve replacement because the outcome is superior (35, 81) . In asymptomatic patients with normal LVEF, management is less clear. One approach is to recommend surgery in patients with proven severe organic MR on the basis that it is highly likely that symptoms or LV dysfunction will develop sooner or later (82); a second approach is to refer for surgery at the first sign of symptoms, a decline in LV function, onset of AF, or increasing pulmonary arterial pressures (83) . As with AS, the watchful waiting approach may result in patients with early symptoms slipping through the net, particularly without functional testing. Equally, misplaced enthusiasm for early surgery might condemn a previously asymptomatic patient to the hazards of surgery and the far-from-trivial risks of a failed repair and a mechanical prosthesis. Current American College of Cardiology/American Heart Association guidelines are explicit in stating that mitral valve repair in asymptomatic patients should only be attempted if there is a 90% expectation that a successful repair can be achieved, and a surgical mortality rate of Ͻ1% and 5-year recurrence rate of Ͻ5% have been suggested as standards in this group of patients (35, 84) . Although this might be possible in expert centers, it is far from clear that is achievable more widely. There is no clear evidence that surgical treatment of functional MR carries a prognostic benefit.
Baseline correlations. COMPARISONS WITH CONTROLS.
There are limited data on levels of natriuretic peptides in MR in comparison with normal controls. In one study of 49 patients with varying degrees of isolated organic MR and an LVEF of Ͼ55%, plasma levels of ANP, BNP, and NTproBNP were greater in both asymptomatic and symptomatic patients with MR compared with controls after adjustment for age, sex, and body surface area (85) . A second study of 78 patients with varying degrees of both organic and functional MR also found increased ANP and BNP levels compared with controls (86) .
SEVERITY OF VALVE DISEASE.
There is a variable relationship between plasma levels of natriuretic peptides and the severity of MR in published studies. A number of studies demonstrated a positive relationship between natriuretic peptides and the severity of both organic and functional MR (87) (88) (89) (90) , whereas others have shown either no correlation or a relationship only on univariate analysis (86, (91) (92) (93) . Findings are summarized in Table 4 . This variability in findings likely reflects heterogeneous patient populations, but the implication is that natriuretic peptides are not a clinically useful marker of the severity of the regurgitation per se. In practice, this is not a particular issue because the severity of regurgitation can usually be determined by echocardiography.
CARDIAC STRUCTURE AND FUNCTION. The majority of studies fail to show a significant association between any of the natriuretic peptides and LVEF (85,86,89 -92) (Table 4) .
Exceptions are a study including patients with organic MR in which there was a weak negative correlation between NT-proBNP and LVEF (r ϭ Ϫ0.25) (93) and a study in which the BNP/ANP ratio showed a similar finding (94) . Similarly, there is no consistent association with right ventricular function, LV diastolic filling parameters, or measures of end-diastolic size (86, 90, 92, 93) . Increased LV end-systolic dimensions or volumes are important markers of ventricular decompensation in chronic MR and are associated with BNP and NT-proBNP in most but not all series (86, 89, 90, 93) as are increased pulmonary arterial systolic pressures (86, 89, 92) . The most consistent, but not universal, association is with LA dimensions or volumes (85, 89, 90, 92, 93) . AF was an independent predictor of BNP levels in one study (91) , but another showed that both ANP and BNP decreased with very large atria in the presence of AF (94) . BNP levels are higher in patients with functional compared with organic MR, but this reflects a greater degree of LV dysfunction with larger end-systolic volumes and greater wall stress (86) . Stratification for LV endsystolic volume index (LVESVI) removed the effect of the etiology of MR. The concept that BNP provides an integrated index of cardiac remodeling including systolic LV dilation, LA dilation, and pulmonary hypertension is an attractive one but is not supported by all studies. Again, this is related to the highly heterogeneous patient populations studied. Table 6 summarizes findings from 4 studies that included data on LVESVI. The majority found that BNP was a marker for increased LVESVI (86, 87, 90) , with the one study with negative findings having a small range of LVESVI (92) . Thus, BNP is a marker for systolic ventricular remodeling in chronic MR but only in the context of a wide range of ventricular volumes and hence probably not useful in identifying the earliest stages of ventricular decompensation. The consistent relationship between BNP and LA size suggests that BNP may be produced by LA myocardium in response to chronic increases in atrial wall stress rather than solely by ventricular myocardium (92) . The relationship to pulmonary arterial systolic pressure is less easy to explain given the lack of relationship between BNP and measures of right ventricular function.
SYMPTOMATIC STATUS. BNP, NT-proBNP, and ANP are all higher in symptomatic than asymptomatic patients after adjustment for the severity of MR and the extent of atrial and ventricular remodeling (85 Abbreviation as in Table 2 .
2045 JACC Vol. 55, No. 19, 2010 Steadman et al. May 11, 2010 May 11, :2034 Natriuretic Peptides in Valvular Heart Disease treadmill exercise testing. The first 167 patients were used as a derivation cohort and the second 102 as a validation cohort. BNP was assayed on samples taken as baseline and 1 year, and patients were followed to a combined end point of death, development of LV systolic dysfunction (LVEF Ͻ60%), or the onset of heart failure (NYHA functional class III or IV). The AUC for the receiver-operator characteristic curve of BNP as a predictor of the combined end point was 0.80 for the derivation cohort and 0.81 for the validation cohort. Stratification of baseline BNP into quartiles gave event-free survival rates at 48 months of 99%, 97%, 93%, and 29%. Using a cutpoint of 105 pg/ml from the derivation cohort, the combined end point occurred in 66% of the validation cohort with a BNP Ͼ105 pg/ml as opposed to 4% with a BNP Ͻ105 pg/ml (p Ͻ 0.00001) with a hazard ratio of 4.7 on Kaplan-Meier analysis (p Ͻ 0.0001). In the validation cohort, BNP Ͼ105 pg/ml was the strongest independent predictor of the combined end point (OR: 4.1), followed by an effective regurgitant orifice area Ͼ55 mm 2 (OR: 3.7) and an end-systolic diameter/body surface area of Ͼ22 mm 2 (OR: 3.1). In a study of patients with functional MR, NT-proBNP Ͼ1,941 pg/ml was second only to a marked increase in the LVESVI (Ͼ82 ml/m 2 ) as an independent predictor of death, with a hazard ratio of 2.17 (p ϭ 0.026), and was the most powerful predictor of death or hospitalization, with a hazard ratio of 3.19 (p Ͻ 0.001) (87) .
Conclusions
The role of natriuretic peptides as cardiac hormones is clear given their close relationship to cardiac structure and function, reflecting LV wall stress and subclinical myocardial dysfunction. In valvular heart disease, they are correlated with disease severity, although this is more reliable in AS than MR, as well as symptomatic status. Determining symptomatic status itself can be difficult even with a rigorous clinical history. Breathlessness in particular is very subjective; in a large group of elderly people, one-third of patients were classified as breathless, using the Medical Research Council Scale, but only one-half of them had any identifiable pathology (95) . Natriuretic peptides could play a role here. Perhaps the most exciting prospect for future use comes from their ability to predict outcome. BNP and NT-proBNP show the most promise. In AS, low levels are good predictors of symptom-free survival and high levels are indicative of subsequent mortality, at least in medically managed patients. High levels may also be strong predictors of perioperative and long-term mortality. In MR, plasma levels are associated with adverse outcomes in both organic and functional MR, and there are preliminary data to suggest that BNP might be a useful predictor of incipient decompensation in asymptomatic patients with organic MR.
In both AS and MR, the difficulty remains in deciding on the optimum timing of surgery in asymptomatic patients. A reliable biomarker that appropriately risk-stratifies such patients would be invaluable. Natriuretic peptides have been extensively studied in valvular heart disease, as we have detailed; however, there are no studies that have tested the hypothesis that early surgical intervention in asymptomatic patients with severe valvular heart disease and elevated levels of natriuretic peptides reduces mortality or improves functional outcome. Additionally, there are many comorbidities that are not uncommon in valvular heart disease, such as CAD, diabetes, and hypertension, and their impact on natriuretic peptide levels has not been clearly established. Whether natriuretic peptides will have a clinically useful role is yet to be proven; prospective, randomized, controlled trials in well-described patient populations are needed before they can be incorporated into the routine management of these challenging and increasingly prevalent patient groups.
